|
1
|
Pavlova NN and Thompson CB: The emerging
hallmarks of cancer metabolism. Cell Metab. 23:27–47. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lu J, Tan M and Cai Q: The Warburg effect
in tumor progression: Mitochondrial oxidative metabolism as an
anti-metastasis mechanism. Cancer Lett. 356:156–164. 2015.
View Article : Google Scholar
|
|
3
|
Han T, Kang D, Ji D, Wang X, Zhan W, Fu M,
Xin HB and Wang JB: How does cancer cell metabolism affect tumor
migration and invasion? Cell Adh Migr. 7:395–403. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lin HM, Nikolic I, Yang J, Castillo L,
Deng N, Chan CL, Yeung NK, Dodson E, Elsworth B, Spielman C, et al:
MicroRNAs as potential therapeutics to enhance chemosensitivity in
advanced prostate cancer. Sci Rep. 8:78202018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sakurai K, Furukawa C, Haraguchi T, Inada
K, Shiogama K, Tagawa T, Fujita S, Ueno Y, Ogata A, Ito M, et al:
Micrornas miR-199a-5p and -3p target the brm subunit of swi/snf to
generate a double-negative feedback loop in a variety of human
cancers. Cancer Res. 71:1680–1689. 2011. View Article : Google Scholar
|
|
7
|
Gu S and Chan WY: Flexible and versatile
as a chameleon-sophisticated functions of microRNA-199a. Int J Mol
Sci. 13:8449–8466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong
Q, Qin L, Wu X, Zheng Y, Yang Y, et al: Identification of miRNomes
in human liver and hepatocellular carcinoma reveals miR-199a/b-3p
as therapeutic target for hepatocellular carcinoma. Cancer Cell.
19:232–243. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tsukigi M, Bilim V, Yuuki K, Ugolkov A,
Naito S, Nagaoka A, Kato T, Motoyama T and Tomita Y: Re-expression
of miR-199a suppresses renal cancer cell proliferation and survival
by targeting GSK-3b. Cancer Lett. 315:189–197. 2012. View Article : Google Scholar
|
|
10
|
Minna E, Romeo P, De Cecco L, Dugo M,
Cassinelli G, Pilotti S, Degl’Innocenti D, Lanzi C, Casalini P,
Pierotti MA, et al: miR-199a-3p displays tumor suppressor functions
in papillary thyroid carcinoma. Oncotarget. 5:2513–2528. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Qu F, Zheng J, Gan W, Lian H, He H, Li W,
Yuan T, Yang Y, Li X, Ji C, et al: MiR-199a-3p suppresses
proliferation and invasion of prostate cancer cells by targeting
Smad1. Oncotarget. 8:52465–52473. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zeng B, Shi W and Tan G: MiR-199a/b-3p
inhibits gastric cancer cell proliferation via down-regulating
PAK4/MEK/ERK signaling pathway. BMC Cancer. 18:342018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu X, Duan H, Zhou S, Liu Z, Wu D, Zhao
T, Xu S, Yang L and Li D: microRNA-199a-3p functions as tumor
suppressor by regulating glucose metabolism in testicular germ cell
tumors. Mol Med Rep. 14:2311–2320. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen BF, Gu S, Suen YK, Li L and Chan WY:
microRNA-199a-3p, DNMT3A, and aberrant DNA methylation in
testicular cancer. Epigenetics. 9:119–128. 2014. View Article : Google Scholar :
|
|
15
|
Deng Y, Zhao F, Hui L, Li X, Zhang D, Lin
W, Chen Z and Ning Y: Suppressing miR-199a-3p by promoter
methylation contributes to tumor aggressiveness and cisplatin
resistance of ovarian cancer through promoting DDR1 expression. J
Ovarian Res. 10:502017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li Q, Xia X, Ji J, Ma J, Tao L, Mo L and
Chen W: MiR-199a-3p enhances cisplatin sensitivity of
cholangiocarcinoma cells by inhibiting mTOR signaling pathway and
expression of MDR1. Oncotarget. 8:33621–33630. 2017.PubMed/NCBI
|
|
17
|
Fan X, Zhou S, Zheng M, Deng X, Yi Y and
Huang T: MiR-199a-3p enhances breast cancer cell sensitivity to
cisplatin by downregulating TFAM (TFAM). Biomed Pharmacother.
88:507–514. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:2015. View Article : Google Scholar
|
|
19
|
Gori S, Porrozzi S, Roila F, Gatta G, De
Giorgi U and Marangolo M: Germ cell tumours of the testis. Crit Rev
Oncol Hematol. 53:141–164. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Winter C and Albers P: Testicular germ
cell tumors: Pathogenesis, diagnosis and treatment. Nat Rev
Endocrinol. 7:43–53. 2011. View Article : Google Scholar
|
|
21
|
von Eyben FE: Chromosomes, genes, and
development of testicular germ cell tumors. Cancer Genet Cytogenet.
151:93–138. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bezan A, Gerger A and Pichler M: MicroRNAs
in testicular cancer: Implications for pathogenesis, diagnosis,
prognosis and therapy. Anticancer Res. 34:2709–2713.
2014.PubMed/NCBI
|
|
23
|
Chieffi P and Chieffi S: Molecular
biomarkers as potential targets for therapeutic strategies in human
testicular germ cell tumors: An overview. J Cell Physiol.
228:1641–1646. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Viatori M: Testicular cancer. Semio Oncol
Nurs. 28:180–189. 2012. View Article : Google Scholar
|
|
25
|
Ferreira LM, Hebrant A and Dumont JE:
Metabolic reprogramming of the tumor. Oncogene. 31:3999–4011. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Porporato PE, Dhup S, Dadhich RK, Copetti
T and Sonveaux P: Anticancer targets in the glycolytic metabolism
of tumors: A comprehensive review. Front Pharmacol. 2:492011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao X, Huang X, Ye F, Chen B, Song C, Wen
J, Zhang Z, Zheng G, Tang H and Xie X: The miR-34a-LDHA axis
regulates glucose metabolism and tumor growth in breast cancer. Sci
Rep. 6:217352016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rizwan A, Serganova I, Khanin R, Karabeber
H, Ni X, Thakur S, Zakian KL, Blasberg R and Koutcher JA:
Relationships between LDH-A, lactate, and metastases in 4T1 breast
tumors. Clin Cancer Res. 19:5158–5169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qiu H, Jackson AL, Kilgore JE, Zhong Y,
Chan LL, Gehrig PA, Zhou C and Bae-Jump VL: JQ1 suppresses tumor
growth through downregulating LDHA in ovarian cancer. Oncotarget.
6:6915–6930. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang J, Wang H, Liu A, Fang C, Hao J and
Wang Z: Lactate dehydrogenase A negatively regulated by miRNAs
promotes aerobic glycolysis and is increased in colorectal cancer.
Oncotarget. 6:19456–19468. 2015.PubMed/NCBI
|
|
31
|
Otero-Albiol D and Felipe-Abrio B:
MicroRNA regulating metabolic reprogramming in tumor cells: New
tumor markers. Cancer Transl Med. 2:175–81. 2016. View Article : Google Scholar
|
|
32
|
Zou S, Gu Z, Ni P, Liu X, Wang J and Fan
Q: SP1 plays a pivotal role for basal activity of TIGAR promoter in
liver cancer cell lines. Mol Cell Biochem. 359:17–23. 2012.
View Article : Google Scholar
|
|
33
|
Archer MC: Role of sp transcription
factors in the regulation of cancer cell metabolism. Genes Cancer.
2:712–719. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hedrick E, Cheng Y, Jin UH, Kim K and Safe
S: Specificity protein (Sp) transcription factors Sp1, Sp3 and Sp4
are non-oncogene addiction genes in cancer cells. Oncotarget.
7:22245–22256. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Beishline K and Azizkhan-Clifford J: Sp1
and the ‘hallmarks of cancer’. FEBS J. 282:224–258. 2015.
View Article : Google Scholar
|
|
36
|
Vizcaíno C, Mansilla S and Portugal J: Sp1
transcription factor: A long-standing target in cancer
chemotherapy. Pharmacol Ther. 152:111–124. 2015. View Article : Google Scholar : PubMed/NCBI
|
